premargin

Middle East Pharmaceutical Industries (Avalon Pharma) appointed Ahmad Shaher Al Tabbaa as Chairman and Hisham Mohammed Attar as Vice Chairman for a four-year term commencing April 16, 2026, and ending April 15, 2030.
Mohamed Maher AlGhannam was appointed as Managing Director and CEO, while Ammar Mamoun AlHajjeh was named Secretary of the Board of Directors.
The Board approved the formation of three key committees: the Audit and Compliance Committee, the Nomination and Remuneration Committee, and the Executive Committee.
Mohamed Maher AlGhannam and Syed Moazam Ali Shah (CFO) were designated as the company's official representatives to the Capital Market Authority (CMA) and the Saudi Exchange.

Element List	Explanation
Announcement Detail	In reference to the announcement made by Middle East Pharmaceutical Industries Co. (the "Company") published on the (Saudi Exchange) dated 12 April 2026 (corresponding to 24 Shawal 1447 AH) regarding the results of the Ordinary General Assembly meeting held on Thursday, 09 April 2026 (corresponding to 21 Shawal 1447 AH), which included the election of the members of the Board of Directors for the new term commencing on 16 April 2026 and for a period of four years, ending on 15 April 2030. The Company is pleased to announce the Board of Directors’ resolution dated 16 April 2026 (corresponding to 28 Shawal 1447 AH) (attached), which includes the following: 1. Approval of the appointment of the Chairman and Vice Chairman of the Middle East Pharmaceutical Industries Company’s Board of Directors. 2. Approval of the formation of the Board of Directors’ Committees. 3. Approval of the appointment of the Board of Directors’ Secretary. 4. Approval of the appointment of the Company’s representatives with respect to the Capital Market Authority (CMA) and the Saudi Exchange Company for all the purposes related to the Law, the Companies Law, their implementing regulations, other relevant regulations, and the rules on the offer of securities and continuing obligations.
Attached Documents	Attached Documents

Element List

Explanation

Announcement Detail

In reference to the announcement made by Middle East Pharmaceutical Industries Co. (the "Company") published on the (Saudi Exchange) dated 12 April 2026 (corresponding to 24 Shawal 1447 AH) regarding the results of the Ordinary General Assembly meeting held on Thursday, 09 April 2026 (corresponding to 21 Shawal 1447 AH), which included the election of the members of the Board of Directors for the new term commencing on 16 April 2026 and for a period of four years, ending on 15 April 2030.

The Company is pleased to announce the Board of Directors’ resolution dated 16 April 2026 (corresponding to 28 Shawal 1447 AH) (attached), which includes the following:

1. Approval of the appointment of the Chairman and Vice Chairman of the Middle East Pharmaceutical Industries Company’s Board of Directors.

2. Approval of the formation of the Board of Directors’ Committees.

3. Approval of the appointment of the Board of Directors’ Secretary.

4. Approval of the appointment of the Company’s representatives with respect to the Capital Market Authority (CMA) and the Saudi Exchange Company for all the purposes related to the Law, the Companies Law, their implementing regulations, other relevant regulations, and the rules on the offer of securities and continuing obligations.

Attached Documents

Middle East Pharmaceutical Industries Co. Announces the appointment of the Chairman and Vice Chairman of the Board, the formation of the Board’s Committees, and the appointment of the Board’s Secretary and the Company’s representatives